139 related articles for article (PubMed ID: 35728342)
1. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry.
Müller V; Hein A; Hartkopf AD; Fasching PA; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lüftner D; Wallwiener M; Beckmann MW; Schneeweiss A; Belleville E; Uhrig S; Wimberger P; Hielscher C; Meyer J; Wurmthaler LA; Kurbacher CM; Wuerstlein R; Untch M; Janni W; Taran FA; Lux MP; Wallwiener D; Brucker SY; Fehm TN; Michel LL
Eur J Cancer; 2022 Sep; 172():13-21. PubMed ID: 35728342
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and survival of de novo and recurrent metastatic breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Edwards M; Lawrenson R
Breast Cancer; 2021 Mar; 28(2):387-397. PubMed ID: 33044617
[TBL] [Abstract][Full Text] [Related]
3. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
4. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
5. Genomic Characterization of
Garrido-Castro AC; Spurr LF; Hughes ME; Li YY; Cherniack AD; Kumari P; Lloyd MR; Bychkovsky B; Barroso-Sousa R; Di Lascio S; Jain E; Files J; Mohammed-Abreu A; Krevalin M; MacKichan C; Barry WT; Guo H; Xia D; Cerami E; Rollins BJ; MacConaill LE; Lindeman NI; Krop IE; Johnson BE; Wagle N; Winer EP; Dillon DA; Lin NU
Clin Cancer Res; 2021 Feb; 27(4):1105-1118. PubMed ID: 33293374
[TBL] [Abstract][Full Text] [Related]
6. The clinicomolecular landscape of de novo versus relapsed stage IV metastatic breast cancer.
Seltzer S; Corrigan M; O'Reilly S
Exp Mol Pathol; 2020 Jun; 114():104404. PubMed ID: 32067942
[TBL] [Abstract][Full Text] [Related]
7. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
File DM; Pascual T; Deal AM; Wheless A; Perou CM; Claire Dees E; Carey LA
Breast Cancer Res Treat; 2022 Nov; 196(1):153-162. PubMed ID: 36008651
[TBL] [Abstract][Full Text] [Related]
8. HR
Torrisi R; Jacobs F; Miggiano C; De Sanctis R; Santoro A
Drugs Context; 2023; 12():. PubMed ID: 36926051
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer.
Yardley DA; Kaufman PA; Brufsky A; Yood MU; Rugo H; Mayer M; Quah C; Yoo B; Tripathy D
Breast Cancer Res Treat; 2014 Jun; 145(3):725-34. PubMed ID: 24706168
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M; Ferreira AR; Di Meglio A; Poggio F; Puglisi F; Sottotetti F; Montemurro F; Poletto E; Bernardo A; Risi E; Dellepiane C; Sini V; Minuti G; Grasso D; Fancelli S; Del Mastro L
Clin Breast Cancer; 2017 Dec; 17(8):601-610.e2. PubMed ID: 28479052
[TBL] [Abstract][Full Text] [Related]
11. Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study.
Lao C; Kuper-Hommel M; Campbell I; Elwood M; Lawrenson R
N Z Med J; 2021 Nov; 134(1545):47-59. PubMed ID: 34788271
[TBL] [Abstract][Full Text] [Related]
12. Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients.
McKenzie HS; Maishman T; Simmonds P; Durcan L; ; Eccles D; Copson E
Br J Cancer; 2020 May; 122(11):1618-1629. PubMed ID: 32231292
[TBL] [Abstract][Full Text] [Related]
13. Does definitive local therapy have a role in select HER2+ de novo metastatic breast cancer patients treated with dual anti-HER2 blockade?
Rosier L; Wang Y; Lee JH; Daily K
Breast Cancer Res Treat; 2022 Jan; 191(2):375-383. PubMed ID: 34787760
[TBL] [Abstract][Full Text] [Related]
14. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Huebner H; Kurbacher CM; Kuesters G; Hartkopf AD; Lux MP; Huober J; Volz B; Taran FA; Overkamp F; Tesch H; Häberle L; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Ruebner M; Untch M; Fasching PA; Janni W; Fehm TN; Kolberg HC; Wallwiener D; Brucker SY; Schneeweiss A; Ettl J
BMC Cancer; 2020 Nov; 20(1):1091. PubMed ID: 33176725
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of De Novo Metastatic Breast Cancer.
Daily K; Douglas E; Romitti PA; Thomas A
Clin Breast Cancer; 2021 Aug; 21(4):302-308. PubMed ID: 33750642
[TBL] [Abstract][Full Text] [Related]
16. Utilizing Data Visualization to Identify Survival and Treatment Differences Between Women With De Novo and Recurrent Metastatic Breast Cancer.
Gilbert A; Williams C; Azuero A; Burkard ME; Kenzik K; Garrett-Mayer E; Meersman S; Rocque G
Clin Breast Cancer; 2021 Aug; 21(4):292-301. PubMed ID: 33309481
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
18. De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis.
Gaillard T; Carton M; Mailliez A; Desmoulins I; Mouret-Reynier MA; Petit T; Leheurteur M; Dieras V; Ferrero JM; Uwer L; Guiu S; Gonçalves A; Levy C; Debled M; Dalenc F; Patsouris A; Bachelot T; Eymard JC; Chevrot M; Conversano A; Robain M; Hequet D
Eur J Cancer; 2021 Oct; 158():181-188. PubMed ID: 34689042
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic factors associated with de novo metastatic breast cancer.
Shen T; Siegal GP; Wei S
Pathol Res Pract; 2016 Dec; 212(12):1167-1173. PubMed ID: 27692496
[TBL] [Abstract][Full Text] [Related]
20. Comparison between de novo and metachronous metastatic breast cancer: the presence of a primary tumour is not the only difference-a Dutch population-based study from 2008 to 2018.
de Maar JS; Luyendijk M; Suelmann BBM; van der Kruijssen DEW; Elias SG; Siesling S; van der Wall E
Breast Cancer Res Treat; 2023 Apr; 198(2):253-264. PubMed ID: 36648694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
